bosentan anhydrous has been researched along with atrial natriuretic factor in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Boheler, KR; Firth, JD; Kaddoura, S; Poole-Wilson, PA; Sugden, PH | 1 |
| Leskinen, H; Ruskoaho, H; Vuolteenaho, O | 1 |
| Chin, BS; Lip, GY | 1 |
| Allen, TJ; Burrell, LM; Cao, Z; Casley, D; Cooper, ME; Davis, BJ; Johnston, CI; Lassila, M; Tikkanen, I; Tikkanen, T | 1 |
| Ikebe, M; Nakayama, Y; Nonoguchi, H; Shimada, K; Tanzawa, K; Tashima, Y; Tomita, K | 1 |
| Horowitz, JD; Oliver, JR; Zhang, Y | 1 |
| Charles, CJ; Espiner, EA; Frampton, CM; Nicholls, MG; Rademaker, MT; Richards, AM | 1 |
| Brookes, ZL; Brown, NJ; Mansart, A; Reilly, CS; Ross, JJ | 1 |
| Brookes, ZL; Brown, NJ; Mansart, A; Reilly, CS; Ross, JJ; Scicluna, JK | 1 |
| Kim, SH; Lee, GJ; Li, W; Park, BM; Yu, L | 1 |
| Chaumais, MC; Cumont, A; Djessas, MRA; Gaignard, P; Guignabert, C; Hebert, G; Huertas, A; Humbert, M; Savale, L; Thuillet, R; Tu, L | 1 |
1 review(s) available for bosentan anhydrous and atrial natriuretic factor
| Article | Year |
|---|---|
New pharmacological strategies for the treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atrial Natriuretic Factor; Bosentan; Calcium; Cardiotonic Agents; Clinical Trials as Topic; Endothelin-1; Heart Failure; Humans; Hydrazones; Muscle Proteins; Neprilysin; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Sulfonamides; Tumor Necrosis Factor-alpha | 2001 |
1 trial(s) available for bosentan anhydrous and atrial natriuretic factor
| Article | Year |
|---|---|
Combined inhibition of angiotensin II and endothelin suppresses the brain natriuretic peptide response to developing heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Bosentan; Cardiac Output; Cardiac Output, Low; Cardiac Pacing, Artificial; Cyclic GMP; Endothelin Receptor Antagonists; Endothelin-1; Female; Infusions, Parenteral; Losartan; Natriuretic Peptide, Brain; Renin; Sheep; Sulfonamides | 2004 |
9 other study(ies) available for bosentan anhydrous and atrial natriuretic factor
| Article | Year |
|---|---|
Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist.
Topics: Actins; Administration, Oral; Animals; Animals, Newborn; Atrial Natriuretic Factor; Biomarkers; Body Weight; Bosentan; Cells, Cultured; Drug Evaluation, Preclinical; Endothelin Receptor Antagonists; Endothelins; Gene Expression Regulation; Hypertrophy, Left Ventricular; Male; Muscle Proteins; Myocardium; Myosin Heavy Chains; Norepinephrine; Organ Size; Polymerase Chain Reaction; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; RNA, Antisense; RNA, Messenger; Sulfonamides | 1996 |
Combined inhibition of endothelin and angiotensin II receptors blocks volume load-induced cardiac hormone release.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atrial Function, Right; Atrial Natriuretic Factor; Biphenyl Compounds; Blood Volume; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Hemodynamics; Hormones; Imidazoles; Losartan; Male; Myocardium; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptides, Cyclic; Plasma Substitutes; Pressure; Protein Precursors; Rats; Rats, Sprague-Dawley; Sulfonamides; Tetrazoles | 1997 |
Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Aspartic Acid Endopeptidases; Atrial Natriuretic Factor; Blood Pressure; Bosentan; Diabetes Mellitus, Experimental; Drug Interactions; Endothelin Receptor Antagonists; Endothelin-Converting Enzymes; Heart; Kidney; Male; Metalloendopeptidases; Myocardium; Neprilysin; Organ Size; Organophosphonates; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Renin; Sulfonamides; Tetrazoles | 2002 |
Regulation of endothelin-converting enzyme 1 in nephrotic syndrome in rats.
Topics: Animals; Aspartic Acid Endopeptidases; Atrial Natriuretic Factor; Bosentan; Cyclic GMP; Endothelin Receptor Antagonists; Endothelin-1; Endothelin-3; Endothelin-Converting Enzymes; Enzyme Induction; Gene Expression Regulation, Enzymologic; Kidney Glomerulus; Male; Metalloendopeptidases; Nephrons; Nephrotic Syndrome; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides; Time Factors | 2003 |
The role of endothelin in mediating ischemia/hypoxia-induced atrial natriuretic peptide release.
Topics: Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Bosentan; Endothelin Receptor Antagonists; Endothelins; Heart; Hypoxia; Male; Myocardial Ischemia; Peptides, Cyclic; Radioimmunoassay; Rats; Sulfonamides | 2004 |
LPS abolishes extrasplenic vasoconstriction to atrial natriuretic peptide: the role of NO and endothelin 1.
Topics: Animals; Antihypertensive Agents; Arteries; Atrial Natriuretic Factor; Blood Volume; Bosentan; Endothelin-1; Enzyme Inhibitors; Hypovolemia; Lipopolysaccharides; Male; Mesentery; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Donors; Penicillamine; Rats; Rats, Wistar; Sepsis; Spleen; Sulfonamides; Vascular Resistance; Vasoconstriction; Veins | 2008 |
Lipopolysaccharide alters vasodilation to atrial natriuretic peptide via nitric oxide and endothelin-1: time-dependent effects.
Topics: Animals; Atrial Natriuretic Factor; Bosentan; Endothelin A Receptor Antagonists; Endothelin-1; Humans; In Vitro Techniques; Lipopolysaccharides; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Rats; Rats, Wistar; Saphenous Vein; Sulfonamides; Time Factors; Vasodilation; Venules | 2009 |
Hypoxia augments NaHS-induced ANP secretion via KATP channel, HIF-1α and PPAR-γ pathway.
Topics: 2-Methoxyestradiol; Anilides; Animals; Atrial Natriuretic Factor; Bosentan; Gene Expression Regulation; Glyburide; Heart Atria; Hydrogen Sulfide; Hypertension, Pulmonary; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; KATP Channels; Male; Monocrotaline; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type III; Organ Culture Techniques; Oxygen; Pinacidil; Potassium Channel Blockers; PPAR gamma; Rats; Rats, Sprague-Dawley; Signal Transduction; Sulfides | 2019 |
Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Bosentan; Cell Proliferation; Cells, Cultured; Cyclic GMP; Disease Models, Animal; Disease Progression; Drug Combinations; Drug Therapy, Combination; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Humans; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neprilysin; Protease Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats, Wistar; Valsartan; Vascular Remodeling | 2021 |